SEC filings and other documents

VMT-a-NET advances toward Phase 3 as cash reserves reach $237M, funding operations into late 2027.

Alpha emitter therapy shows high efficacy and safety in NETs, with phase III readiness advancing.

VMT-α-NET demonstrates high response rates as pivotal trial planning and manufacturing expansion progress.

Advanced clinical pipeline, raised $164M, and expanded manufacturing; cash runway into late 2027.

Strong clinical results, scalable manufacturing, and robust pipeline drive growth prospects.

Clinical pipeline advances with strong safety, efficacy, and funding to support growth into 2027.

Lead-212 radiopharmaceuticals show high efficacy and safety, with pipeline and manufacturing expansion.

Lead clinical programs advance with strong safety data and funding into late 2026.

VMT-α-NET shows 44% response and strong safety in NETs, supporting registrational advancement.

Clinical pipeline advanced and cash reserves support operations into late 2026.

Q1 2025 saw clinical progress, manufacturing expansion, and a net loss of $18.2M.

Lead-212 platform advances with expanding manufacturing and promising early clinical results.

Lead-212 radiopharmaceuticals show promise in diverse tumors, with strong pipeline and funding.

Lead-212 therapies show early promise in cancer trials, with robust safety and global interest.

VMT-α-NET demonstrated strong safety and durable responses, supporting further dose escalation.

Clinical-stage radiopharmaceuticals show strong early results and expansion, backed by solid funding.

Advanced clinical pipeline and manufacturing expansion, with $227M cash to fund growth into 2026.

Promising clinical data and expanding pipeline highlight advances in lead-based radiotherapeutics.

Strong early efficacy and safety in radioligand pipeline, with key data and trials ahead.